CRISPR THERAPEUTICS AG (CRSP)
CH0334081137 - Common Stock
Bullish Trendline Has Never Failed Crispr Therapeutics Stock
Crispr Therapeutics stock is within one standard deviation of a historically bullish trendline
First Week of CRSP May 31st Options Trading
3 Magnificent Stocks That Could Double or More by 2030
There's no guarantee these stocks will double by 2030, but their growth prospects look great.
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for April 2024
In a stock picker’s market, here are three biotech stocks analysts believe have a chance to outperform the market in 2024.
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
These rising drugmakers have serious arguments in their favor.
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
These stocks, a bargain today, are players to hold on to for the long term.
Oversold Conditions For CRISPR Therapeutics (CRSP)
Better Growth Biotech Buy: Iovance Biotherapeutics vs CRISPR Therapeutics
These companies are in the early days of their growth stories.
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
ZUG, Switzerland and BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
3 Unstoppable Stocks to Buy Hand Over Fist in April
These stocks have exceptionally bright prospects.
Crispr Stock, A Cathie Wood Holding, Dives For The Fifth Straight Week — Here's Why
The company is working to launch its Vertex-partnered gene-editing drug for sickle cell disease and beta thalassemia.
3 Biotech Stocks That Could Be Multibaggers in the Making: March Edition
Discover these three biotech stocks set for major gains with groundbreaking health solutions. Invest in the future of medicine.
3 No-Brainer Healthcare Stocks to Buy Right Now for Less Than $1,000
Each of these three companies are entering a new era of growth.
Interesting CRSP Put And Call Options For May 3rd
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
The price could be right for these three biopharma stocks.
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks.
3 Biopharma Stocks Predicted to Soar in Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biopharma stocks have been among the most popular and well-performing stocks th...
Is It Too Late to Buy CRISPR Therapeutics Stock?
The biotech has been making a lot of noise since late last year.
The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024
These undervalued Cathie Wood stocks capture her favorite trends and remain undervalued even as the wider tech sector surge.
The 3 Most Undervalued Cathie Wood Stocks to Buy in March 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even with the wider market rebound, Cathie Wood hasn’t quite recaptured h...
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation.
CRISPR Therapeutics Proposes New Appointment to the Board of Directors
ZUG, Switzerland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Christian Rommel, Ph.D., to its Board of Directors at the Company’s annual general meeting to be held this year.
Interesting CRSP Put And Call Options For April 26th
The Top 3 Biotech Stocks to Buy in March 2024
Although the biotech sector puts the benefits and risks in plain sight, three top biotech stocks to buy shine for investors.
Here's Why CRISPR Therapeutics Stock Climbed 34% in February
The biotech company keeps moving closer to bringing its promising first gene therapy to market.
ChatGPT Stock Predictions: 3 Biotech Companies the AI Bot Thinks Have 10X Potential
Here are three ChatGPT stock predictions for the most unpredictable of biotech stocks that might just have 10x potential.
CRISPR Therapeutics Stock Has 32% Upside, According to 1 Wall Street Analyst
This company's fortunes are likely to improve, and soon.
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
The futures for these two beaten-down stocks could be brighter than their recent pasts.
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
Both companies are working on treatments for genetic disorders.
3 Biotech Stocks Bound to Blast Off By 2029
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks have long been a speculative, albeit rewarding way to invest in ...
3 Biotech Stocks Bound to Blast Off By 2029
Biotech stocks are risky, but rewarding. These three biotechs specifically could see exponential gains in the coming years.